Tocagen shares collapse as investigators read last rites for PhIII brain cancer study
Two years after going public on the promise of a new approach to fight recurrent brain cancer, Tocagen has hit the wall.
The biotech bluntly reported the failure of their pivotal Phase III study of a 2-part drug — Toca 511 & Toca FC — for high-grade glioma. Part 1 uses a vector to attack cancer cells in the brain and deliver a gene for an enzyme, while part 2 is a prodrug — 5-fluorocytosine (5-FC) — that converts into the anti-cancer therapy 5-FU.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
